Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET
Rhea-AI Summary
Teva (NYSE:TEVA) will publish its second quarter 2026 financial results on July 29, 2026 at 7:00 a.m. ET, followed by a conference call and live webcast at 8:00 a.m. ET. Investors must register in advance for dial-in details. A webcast replay will be available within 24 hours.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – TEVA
On the day this news was published, TEVA gained 2.29%, reflecting a moderate positive market reaction. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $806M to the company's valuation, bringing the market cap to $36.02B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Conferences,earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 19 | Earnings call schedule | Neutral | -2.4% | Set date and time for Q1 2026 results release and conference call. |
| Dec 12 | Earnings call schedule | Neutral | +1.1% | Announced Q4 2025 results release timing and investor conference call. |
| Sep 25 | Earnings call schedule | Neutral | -0.1% | Scheduled Q3 2025 results release and webcast for investors. |
| Jun 25 | Earnings call schedule | Neutral | -2.6% | Outlined Q2 2025 earnings release and follow-up conference call plan. |
| Mar 27 | Earnings call schedule | Neutral | -2.6% | Announced Q1 2025 results publication time and investor call logistics. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Routine earnings conference call announcements have typically led to modestly negative single-day moves for TEVA.
Historical Comparison
In the past year, TEVA issued five similar earnings-call scheduling releases, with an average one-day move of -1.32%, indicating markets usually react only modestly to this type of routine announcement.
Regulatory & Risk Context
Reported short interest reflects relatively low bearish positioning, suggesting limited short-squeeze potential and generally moderate incremental volatility from covering activity alone.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TEL AVIV, Israel and PARSIPPANY, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2026 financial results on Wednesday, July 29, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin.
A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations.
Following the conclusion of the call, a replay of the webcast will be available within 24 hours on Teva's website.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This Document and the presentation at the conference call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, to sustain and focus our portfolio of generic medicines, and to execute on our organizational transformation and to achieve expected cost savings; our significant indebtedness; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in our Quarterly Report on Form 10-Q for the first quarter of 2026, and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned “Risk Factors” and “Forward Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
Teva Media Inquiries
TevaCommunicationsNorthAmerica@tevapharm.com
Teva Investor Relations Inquiries
TevaIR@Tevapharm.com
